Leucid Bio to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Leucid Bio is a privately-held biotechnology company dedicated to the development of cell therapies for the treatment of solid tumours using the Company's proprietary lateral CAR platform. The Company's lead asset, LEU011, is an autologous CAR-T cell therapy targeting NKG2D ligands, which are expressed on more than 80% of human tumours. In addition, LEU011 co-expresses the chemokine receptor CXCR2 which is engineered to enhance cell trafficking and tumour infiltration. For more information, please visit the Leucid Bio website at www.leucid.com

LONDON, 28/08/2025 (informazione.news - comunicati stampa - salute e benessere)

Leucid Bio is a privately-held biotechnology company dedicated to the development of cell therapies for the treatment of solid tumours using the Company's proprietary lateral CAR platform. The Company's lead asset, LEU011 , is an autologous CAR-T cell therapy targeting NKG2D ligands, which are expressed on more than 80% of human tumours. In addition, LEU011 co-expresses the chemokine receptor CXCR2 which is engineered to enhance cell trafficking and tumour infiltration. For more information, please visit the Leucid Bio website at www.leucid.com

 

View original content:https://www.prnewswire.co.uk/news-releases/leucid-bio-to-participate-in-morgan-stanley-23rd-annual-global-healthcare-conference-302540266.html